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Abstract
Diabetes has been on the rise globally. Although many factors
contribute to the increasing risk and manifestation of this disease
lack and decreased physical activity/ exercise stands out as one of the
major factors. Treatment interventions for prediabetic and diabetic
patients include diet and lifestyle changes with enhanced physical
activity/ exercise. Several types of physical activity are available for
these patients but, recommendations have to be made on an individual
basis after giving due consideration to the co morbidities and other
risks and barriers. Implementation of progressive resistance therapy
may be successful in maintaining glucose homeostasis in diabetic
patients.
Keywords: Diabetes; Aerobic exercise; Resistance exercise;
Myostatin; miRNA; Osteocalcin

Introduction

Recently, there is an increase in the number of individuals
diagnosed with diabetes- A medical disorder associated with
an imbalance in glucose homeostasis. Many factors contribute
to this condition and one of the most important factors, in
addition to diet, is a lack of Physical Activity (PA)/ Exercise
(EX) and adoption of partial or complete sedentary lifestyle.
PA is the daily activities an individual performs in addition
to planned EX regimens. Interventions that include increased
physical activity/ exercise along with medications are highly
recommended. However, with several different options available
for EX regimens, it is important to select the most beneficial
form of EX for individuals, considering the existing lifestyle and
co-morbidities. This review focuses on the various factors and
mechanisms that are affected by diabetes and physical activity.
PubMed and Medline were the databases used to collect relevant
literature, and they are compiled and discussed. In addition, the
risks and barriers associated with the different types of PA are
also discussed.

Diabetes

Diabetes is a medical condition that affects 347 million people
around the world. In 2014, the global prevalence of diabetes was
Symbiosis Group

estimated to be 9% among adults aged 18 and above [1]. In the
United States, in 2012, 29.1 million people (9.3% of the population)
had diabetes [2] and diabetes remained the 7th leading cause of
death in the US, in 2010. The total cost of diagnosed diabetes is
$245 billion in 2012. This included $176 billion in direct medical
expenses for emergency care, hospitalization, office visits and
medications and $69 billion as indirect costs such as days absent
from work, reduced productivity, unemployment due to diabetesrelated disability and lost productivity due to early mortality [3].

There are two major types of chronic diabetic conditions
identified – Type I Diabetes Mellitus (T1DM) and Type II Diabetes
Mellitus (T2DM). A temporary diabetic condition is also seen
during pregnancy in some women and is termed gestational
diabetes mellitus. Diabetes, in general, is characterized by
increased circulating blood sugar and uncontrolled diabetes.
These adverse effects lead to many complications that affect
several organs like skin, eye, kidney, heart, nerves, bone, etc.
resulting in ketoacidosis, high blood pressure, stroke and
severe Diabetic Neuropathy (DPN) of the extremities [4-7].
DPN affects predominantly the distal segments of the lower
limbs impairing walking and daily activities [4,7]. In addition,
diabetic patients have decreased skin thickness, increased skin
hardness, thickened tendons, muscle atrophy, impairment and
activation delays, and decreased bone mineral density, limited
mobility at joints, less thick fat pad and gait changes [8-14]. The
severity of the complications advances with age and adds to the
complications of the normal aging process.
Muscle strength of the upper and lower body correlated with
measures of diabetic complications especially with sensory and
autonomic functions [6]. Loss of muscle strength is associated
with atrophy of ankle and foot muscles due to denervation caused
by loss of motor axons combined with insufficient innervations
[15]. Also, Peripheral Arterial Disease (PAD), due to diabetes,
may aggravate muscle weakness and atrophy of limbs including
the upper limbs [16] where handgrip strength decreased with
age [8].
T1DM is usually diagnosed in children and is characterized by
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a lack of insulin due to non-functional or destroyed pancreatic β
cells. The auto-destruction of β cells [17] is controlled genetically.
In addition, T1DM patients have greater utilization of fatty acid
and oxidation as well as, decreased glucose utilization [18]. The
kidneys are overworked in T1DM patients, as these patients
have higher hyperfiltration rate due to increasing glomerular
hypertension in the kidneys [19] and undergo diabetic
nephropathy [20]. However, only 5% of all the individuals
diagnosed with diabetes are diagnosed with T1DM, which is
about 1.25 millions of Americans [21].
T2DM, on the other hand, is seen in adults and older
individuals. These patients usually develop insulin resistance
(IR) as underutilization of insulin leads to increased circulation
in the blood resulting in decreased production of insulin, and
eventual failure of β cells [2]. A Majority of the total number of
patients diagnosed with diabetes 90-95% is T2DM [2].

Actually, IR starts before β cell damage and shut down of
the pancreas [22-27]. For insulin-dependent glucose transport,
insulin first binds to the insulin receptor on the plasma
membrane and triggers the signaling pathway to mobilize
glucose from the cells. After insulin binds to its receptor, Insulin
Receptor Substrate-I (IRS-I) is phosphorylated and this activates
Phosphoinositide-3 Kinase (PI3K) and protein kinase B (Akt),
leading to translocation of glucose transporter 4 (GLUT4) to
the membrane and subsequent transportation of glucose into
the cells. In the case of IR, IRS-1 phosphorylation is defective
so is the activation of PI3K and Akt [2], therefore, GLUT4 is not
translocated to the membrane, thus, decreasing the uptake of
glucose into the cells. This leads to dysfunction in skeletal muscle
with (a) IR in the muscles [28]; (b) buildup of intramuscular
triglycerides [29,30]; (c) impaired mitochondrial function [2,31];
(d) impaired glycogen synthesis; and (e) lipid accumulation
around and within the muscles [2]. Several factors cause IR, such
as inflammation, reduced mitochondrial content or dysfunction
mainly by accumulation of lipid intermediates in skeletal muscle
[32]; reduced insulin signaling leading to decreased insulinstimulated GLUT4 translocation and aging [33].
In diabetic individuals, muscle function is compromised.
Muscles are influenced greatly, by the levels of Myostatin, a
protein that inhibits muscle differentiation and growth [34-37]
and attenuates muscle fiber protein accretion [38-40]. Myostatin
has direct metabolic effects on other tissues like adipose and liver
as well [41]. In T2DM, there is an increase in the mRNA levels of
Myostatin [42], and this is inversely related to insulin sensitivity
which directly influences glucose uptake and utilization in a
cell-specific manner [41]. Myostatin also affects glucose uptake
indirectly, through Tumor Necrosis Factor-α (TNF-α) expression,
which antagonizes insulin-mediated glucose uptake [43]. In
addition, mutations in Myostatin gene and impaired Myostatin
protein leads to increase in muscle mass in animals and humans
[39, 44-46].
Diet plays an important role in manifestation, establishment,
and progression of diabetes. As glucose metabolism is affected,
it is very logical to focus on carbohydrate intake in diabetic
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patients and has been the practice for a long time. Interventions
on regulating carbohydrate intake reduced circulating glucose
levels. However, there is increasing evidence pointing towards
the role of excessive intake of fats also leading to IR. T2DM
patients show increased levels of fat uptake soon after meals
[47]. Lipid accumulates in adipocytes within muscle tissues and
fibers [48] which are one more factor that can cause IR [30,49].
In addition, chronic overload of calories with increased adiposity
also leads to IR [50] and hypocaloric diet reduces both fat and
lean mass [51]. IR, in the skeletal muscles, also develops when
there is increased H2O2 production in the mitochondria as a
result of acute and chronic intake of high-fat diet [52]. Moreover,
high-fat diet-induced IR and glucose intolerance was decreased
in mice that had mutated Myostatin along with decreased TNF-α
level in muscle and adipose tissue [53]. Therefore, myostatin
down-regulation may be beneficial to diabetic patients.
Diabetic patients also exhibit a faulty energy balance. This
is attributed to decreased mitochondrial density, size and
ultrastructure [54], and impairment of the oxidative capacity of
mitochondria in the skeletal muscle [55]. The Electron Transport
System (ETS) housed in the mitochondria, and responsible for
producing most of the energy molecules-Adenosine Triphosphate
(ATP), is also impaired [56]. The hydrogen molecules that
are necessary for ATP production enter the ETS from the
TCA cycle and β oxidation through Nicotinamide Adenine
Dinucleotide (NAD). Higher levels of reduced Nicotinamide
Adenine Dinucleotide (NADH) production from the Tricarboxylic
Cycle (TCA) and β oxidation are reported from muscle cells of
T2DM patients [57]. This results in a buildup of high reducing
equivalents in energy metabolism, leading to the accumulation of
acetyl-CoA, ceramides, and diacylglycerols which correlate with
IR and altered insulin cascades [58].
Oxidative stress is one more factor that may play a role in
the development of diabetes [59,60]. Oxidative stress increases
with aging [61] and a combination of low intake of antioxidants
with decreased PA contributed to the escalation of oxidative
stress [52,62]. One of the molecules that contribute to oxidative
stress is nitric oxide (NO). Many metabolic reactions in the
body are mediated by NO, which is produced with the help of
the enzyme Nitric Oxide Synthase (NOS). NOS are produced
in several different organs of the body including pancreatic β
cells [63]. In T1DM, β cell degradation is associated with NOS,
which is associated with increased pro-inflammatory cytokines
that induce apoptosis of cells [64]. However, dual effects of
NO have been reported. Depending on the NO concentration,
anti-apoptotic or pro-apoptotic effects may occur [65]. At high
concentrations, excessive NO is detrimental to the β cells and at
low concentrations NO protects these cells. It is also important
to note that under IR and T2DM conditions, there is increased
circulation of NOS inhibitor in the plasma which results in
decreased NO production – a natural adaptation of the body to
reduce NO production. On the other hand, when there is impaired
glucose-stimulated insulin secretion (GSIS), NO production is
enhanced [66]. Therefore, normal functioning of the GSIS is
necessary, to avoid the deleterious effects of NO. Moreover,
insulin can also increase NOS activity [67].
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During the last decade, the importance of microRNA (miRNA)
in the regulation of metabolism had been brought to light.
miRNA are small molecules that play an important role in the
eventual expression and translation of mRNA and proteins. They
have been implicated in glucose homeostasis and IR as well.
Interestingly, miRNAs’ are associated with changes in fat mass
and IR in children [68]. Silencing certain miRNA’s like miR103 and
miR107 improved glucose homeostasis and insulin sensitivity
while other miRNA’s like miR103 and miR107 impaired glucose
homeostasis [69]. Glucose tolerance and IR is also modulated by
Let-7. Overexpression of Let-7 led to IR [70] and has been found
at higher levels in T2DM patients [71]. miRNA’s such as miR133a
and miR206 were downregulated in T2DM patients and an
inverse relationship between IR and miR133a exists [72].

Recently, Osteocalcin (OC), a protein secreted by bone cells
and important for bone formation has been shown to play an
endocrine role in influencing insulin secretion and sensitivity.
Undercarboxylated OC (UnOC) fraction increased insulin
secretion and sensitivity and decreased visceral fat in males and
females [73]. Increase in serum OC and UnOC levels, improved
insulin secretion and/or sensitivity in humans [74,75]. Lack of
OC led to glucose intolerance in muscles [76]. Mice, genetically
modified to increase UnOC are protected from T2DM and obesity
[76]. Injection of OC improved glucose tolerance and insulin
sensitivity in high fat fed mice [76]. Mice treated with intermittent
OC injections displayed more mitochondria in their skeletal
muscles and increased energy utilization. In addition, they were
protected from diet-induced obesity, improved glucose handling,
prevented the development of T2DM, and liver steatosis [76].
Interestingly, mice lacking OC have decreased β cell proliferation
[75]. Therefore, OC may be used as treatment option along with
medications, diet modifications, and PA interventions.

Physical activity/ Exercise

Global industrialization is responsible for drastic lifestyle
changes in humans. One major drawback is the lack and/or
reduction of PA, which is essential for maintaining health and
healthy aging. Lack of sufficient daily PA is an underappreciated
primary cause of most chronic conditions [77]. Therefore, there
is increasing emphasis on maintaining PA and EX regimen
throughout an individual’s lifetime. PA/EX during childhood
influences many organ systems in the body to function and develop
normally, in addition to reducing obesity and complications
that arise from diabetes. In adults, also PA/ EX is encouraged to
reduce the risk of developing several health issues that may arise,
during and after middle age. The elderly are more susceptible to
frailty, and a daily EX regimen is emphasized to maintain better
health, thereby, improving the quality of their life [78]. There
are reports of age-related decreases in muscle mass, and EX
regimen increased muscle mass and strength as one age [79].
Convincing evidence suggests that sedentary lifestyle increased
the risk of cardiovascular disease (CVD) in T1DM patients
[80]. In addition, inactive muscles are not capable of removing
oxidative intermediates due to insufficient electron transport
and results in lipid toxicity [81,82]. Moreover, continued longterm reductions in PA/EX and inactivity are the primary causes
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of IR [52,83]. Daily PA reversed the risk of development of
diabetes in prediabetic patients [52]. Furthermore, muscle loss
occurs with aging and there is a decline in aerobic capacity with
a dramatic decrease in PA/EX [51,84]. A Normal function of an
individual is dependent on sufficient aerobic capacity and muscle
strength [51]. Therefore, an increase daily PA and a continuous
EX regimen are important to avoid several medical complications
including diabetes.
There are several benefits of EX-(a) decreased mortality
up to 40%and lower utilization of health care services [85-94];
(b) prevention of Coronary Heart Disease (CHD) [95,96]; (c)
decreased lipid levels [97,98]; and (d) body composition [99].
With regular EX, primary and secondary prevention of several
chronic conditions including diabetes has been reported [51].
Regular EX also decreased glucose levels and increased insulin
receptors effectiveness [100].
EX can be of different types-aerobic EX-involves a large group
of muscles. This EX regimen is for extended periods of time
and includes multiple repetitions. It also includes endurance
EX for both the muscles and heart and is reported to increase
mitochondrial abundance and aerobic capacity [101]. On the other
hand, resistance EX (REX) involves a movement of high loads
using machines or weights or both and the number of repetitions
is relatively less [102,103]. This is reported to increase muscle
mass in middle-aged and elderly [101]. Both aerobic EX and REX
are associated with decreased risk of T2DM. Even a single bout of
muscle contraction increased insulin sensitivity in animals and
humans [104-113].

Another important fact is that EX can also induce non-insulin
dependent uptake of glucose. For example, IR patients show
contraction mediated uptake of glucose through calcium and
adenosine monophosphate-activated protein kinase (AMPK)
[114,115] with an increase in AMPK α 2 mediated glucose uptake
after EX [116]. The intensity of EX controls the uptake of glucose
and sometimes both pathways may be involved in this. Whole
body strength training for 16 weeks shows improved homeostatic
model assessment-IR (HOMA-IR) in T2DM Hispanic adults [117]
and increased hepatic insulin sensitivity [28].

EX influences NOS, a membrane protein found in the muscle
fibers, and is increased in many disease conditions [118,119].
There are three kinds of NOS-eNOS which is co-localized
with mitochondrial markers in muscle fibers [118]; iNOS that
increased under conditions of inflammation and the presence of
pro-inflammatory cytokines [120,121]; and nNOS that is found
in the outer membrane of muscle fibers and neuromuscular
junctions [119]. During EX, NO production is increased initially
due to a burst of the NOS activity [122]. NO production is induced
by an increase in pro-inflammatory cytokines due to EX, which
supplies oxygen during vigorous EX [123]. Prolonged treadmill
EX, also increased protein expression of nNOS and eNOS and the
contractile activity of skeletal muscles [122,124,125].
EX is also influenced by miRNA’s as they control muscle
proliferation, differentiation and apoptosis [126] and regulate
the aging process and changes in skeletal muscles [127-129].
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During aging, in mice, the quadriceps muscles expressed
upregulated miR7, miR206; miR468, miR542, and miR698 while
miR124a, miR181a, miR221, miR382, miR434, miR455 were
downregulated [130]. In Rhesus monkeys, miR15a, miR18a,
miR144, and miR451 were up-regulated and miR181a/b was
downregulated with aging [131]. Both aerobic EX and REX
influenced the expression of different miRNAs. During aerobic
EX miR181, miR1 and miR107 are up-regulated and miR23 is
downregulated in mice [132]. But in humans, miR1 and miR133
increased before EX, rather than after EX [133] in several muscles.
REX down regulated muscle specific miR-1 and miR133a, in mice
[134]. In humans, miRNA up-regulation and downregulation was
reported based on responders with reference to hypertrophy
of vastus lateralis muscles [135]. Downregulation of miR26a,
miR29a and miR378 was reported in low responders with
upregulation of miR451. There were 15 other miRNAs’ that were
not affected by REX. These miRNA’s may modulate yet another
pathway-the mammalian target of rapamycin (mTOR) signaling
pathway, which is activated during muscle protein anabolism
and REX [135]. REX also increased insulin-like growth factor-I
(IGF-I) and decreased miR1 which may result in increased muscle
cross-sectional area, in elderly men and women after EX [136].
In addition, EX also increased UnOC this had potentially positive
effects on glucose tolerance [73].

Impact of exercise on diabetes

T1DM: In T1DM individuals, aerobic EX maintained glycemic
control and decreased the amount of insulin required to maintain
circulating glucose levels, although HbA1cdid not change [17].
After EX, insulin in pancreatic β cells increased and insulin
secretion by the pancreas also enhanced. It also stimulated the
uptake of glucose by muscles and supported muscle contraction.
In addition, muscle cells were protected from oxidative damage
[137-142]. Short term and long term aerobic EX also increased
GLUT4 [142,143] which is required for glucose transport into the
cells.
NOS is highly influenced by EX. Interestingly, although
GLUT4 mediated transport of glucose is independent of NO, NOS
activity enhanced glucose transport and the NOS inhibitor-LNG-Monomethyl Arginine (L-NMMA) attenuated glucose uptake
[124]. At low concentrations, NOS can positively influence insulin
secretions while at high concentrations it may have a negative
influence on pancreatic β cells and inhibit insulin secretion
[63]. Therefore, TIDM patients may have to increase the intake
of the diet containing anti-oxidants, before EX, to counter the
production of NO.

EX is an indispensable component of treatment for patients
with T1DM [144]. Even low-intensity EX helps [17] and Stretching
EX decreased T1DM neuropathy and pain [145]. However, it has
been reported that moderate EX helped in declining glucose
levels rapidly during the exercise and slowly reversed back after
the exercise when compared to high-intensity EX and REX [146].
High-intensity EX programs showed great improvements in
insulin response to oral glucose load compared to lower intensity
aerobic EX [147]. Therefore, the overall impact on circulating
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glucose levels were attained more with intermittent moderate
EX and some high-intensity EX.

T2DM: In insulin resistant middle-aged men, aerobic EX
decreased muscle and plasma myostatin and this strongly
correlated with insulin sensitivity and diabetic patients [148]. In
mice, there was decreased the circulation of myostatin, insulin
and glucose levels [148] after EX, which decreased IR. Aerobic
training increased insulin sensitivity in T2DM patients [149,150].
In addition, aerobic EX in T2DM patients reversed advanced
glycation in kidney and ameliorated the early signs of diabetic
nephropathy [151]. Kidney function is also influenced by EX. There
are reports that there is reduced glomerular mesangial volume
and decreased albumin excretion, a level of lipid peroxidation
and fibrogenesis in glomerular mesangium [152-154]. Moreover,
improved cardiac function may also protect kidney function after
EX [155]. Aerobic EX showed increased glucose disposal rate in
these patients [156]. In addition, treadmill EX in rats increased
insulin sensitivity, improved insulin-mediated capillary
recruitment in combination with augmented muscle glucose
uptake [137].
Endurance training in T2DM individuals increased the
expression of GLUT4 protein and mRNA [157,158]. EX also
decreased glucose-stimulated insulin levels [159] and myostatin
[41]; especially high bouts of Endurance EX decreased myostatin
mRNA levels [160,161]. Furthermore, myostatin null mice
displayed decreased endurance performance and energy is
regulated by increased mitochondrial enzymes such as citric
synthase and succinate dehydrogenase [162,163]. An important
fact is that levels of myostatin mRNA is different depending on
the time after EX [164]. Another way REX can influence muscle
maybe by decreasing skeletal muscle myostatin mRNA expression
and plasma protein levels [165-170]. However, some reports on
REX did not show the same benefits [171,172] and this may be
due to differences in the experimental protocols such as - terms
of rest, repetition, a number of contractions, intensity, training
state and biopsy sampling time.

Many benefits of REX have been reported in T2DM patients.
In addition, to decreasing neuropathy and pain, REX improved
the glycemic index, HbA1C, adiposity and muscle strength
[145,173,174], it also reduced fasting insulin, increased insulin
sensitivity, glucose disposal rates and improved glucose
tolerance [175-179]. REX increased glucose uptake in muscles
by increasing and translocating GLUT4 to the plasma membrane
[180]. In addition, REX also increased skeletal muscle crosssectional area, muscle cell mitochondria [181] and improved
mitochondrial function [182-184].

Risks and barriers of EX: Many patients have reported
several difficulties in fulfilling the EX regimens recommended to
them. Some of the problems they face may include allocation of
time; work schedule, weather, proximity and access to facilities,
lack of motivation [185]. Among those who have low economic
status, several psychological factors, like embarrassment and
fear of failure, negative body image and chronic disease stigma
that needs vigilance during PA/EX (especially among T1DM
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patients with fear of hypoglycemia) [186] are also barriers that
contribute to non-compliance. Other obstacles include numerous
intrapersonal reasons like lack of energy, lack of time due to
other leisure activities and perceived competencies, as well
as interpersonal reasons such as family, friend peer support,
environmental/organizational factors, opportunity, resources,
etc. [77,187-189].
Although PA/EX is recommended for healthy living, it is
associated with several risks as well. Usually high intensity, as
well as rapid increase in intensity is detrimental for the patients.
One very dangerous side-effect is the late onset of hypoglycemia
after EX, especially in T1DM individuals. Aerobic EX caused acute
risk of hypoglycemia [190], while intermittent and REX had the
lowest likelihood of hypoglycemia [185,191]. Another important
physiological change is that moderate and exhaustive EX may
generate oxidative stress, which can enhance IR [192]. Therefore,
when interventional methods are recommended, a combination
of several factors such as intensity of EX and co-morbidities
including CVD, stroke, etc. should be taken into consideration.

Summary

In order to successfully reduce the risks of diabetes in humans
and maintain a healthy life with diabetes, significant multiple
lifestyle changes seems to be the best approach [193-199]. These
changes include diet modifications and PA/EX with medicines
[200,201]. Consumption of decreased carbohydrates and fats,
with the inclusion of moderate to high amounts of fiber, will be
the major dietary changes for prediabetic and diabetic patients.

Diet adjustments should accompany changes in PA/EX as
well. Both T1DM and T2DM will benefit from these changes.
Although T1DM patients may have to continue taking insulin,
the amount of insulin can be reduced significantly. Regular
EX is important as it reduced HbA1C in T1DM [185], however,
moderate caloric restriction intake with PA reduced fat mass
[202] can be beneficial too.
T2DM patients may benefit more extensively with diet
and lifestyle changes. Non-diabetic children of T2DM and IR
T2DM patients showed decreased insulin sensitivity, muscle
mitochondrial density, mitochondrial electron transport and
insulin-mediated skeletal muscle glucose uptake [22,23,56,203],
putting them at high risk of developing diabetes. Such individuals
can delay the onset of diabetes by increasing their PA/ EX.
Independent of the type of EX, both prediabetic and diabetic
patients showed benefits with increased PA by improving insulin
sensitivity and maintaining glucose homeostasis. Moreover, the
habitual physical activity may prevent and postpone non-insulin
dependent diabetes [100]. Aerobic EX is good, so is repetitive
EX [204]. The overall an increase in PA, increased post-receptor
insulin signaling increase in GLUT4 mRNA and protein levels
[63,157], glucose synthase [205], hexokinase [206], β cell
function [146], An influx of glucose to muscles, enhanced muscle
capillarization and blood flow [207,208]. Increased blood flow,
stimulated NO which induced smooth muscle relaxation and
vasodilation [209]. However, REX may be better than aerobic

Copyright:
© 2016 Banu

EX, and may result in program retention and success of the
interventional objectives [185].

As mentioned earlier, EX can affect several pathways to
maintain glucose homeostasis. Apart from increasing insulin
sensitivity and mobilizing glucose into the cells, it can influence
the insulin signaling pathway through miRNAs’ to stimulate
glucose uptake. Another protein that is impacted due to EX is OC,
which increased insulin secretion, sensitivity, and mitochondria
in the muscles, thereby, affecting the energy balance which is
disrupted in diabetes [75].

Conclusion

In conclusion, it is established that people with moderate
to high levels of EX have lower mortality rate and utilization of
health care services. However, physical fitness is dependent on
nutritional status, dietary and smoking, genetics, socio-economic
factors and PA. In addition, it also depends on pulmonary and
muscle function health status of other organ systems, medications,
and orthopedic limitations [77,210]. To have attainable goals,
which may be more pleasant and an inspiring experience [211],
graduated physical activity with small increments and long term
goals on the health is recommended [61]. Therefore, progressive
resistant therapy (PRT) is safe and an effective EX regimen,
which [212] promotes favorable energy balance and decreased
visceral fat deposition with an increase in basal metabolism
and activity will be more beneficial. It also improved insulin
sensitivity and glycemic control. More importantly, it is safe for
frail elderly individuals and patients with co-morbidities like
CVD and obesity. Moreover, PRT increased glucose disposal
rates, glycogen storage capacity, GLUT4 receptors in skeletal
muscle and insulin sensitivity [212]. However, it is important to
have good glycemic control for EX to benefit [17].

Acknowledgments

The author thanks, Ms. Vaijayanthi Rajendran for collecting
the literature and Mr. Robert Salazar for critically reading the
manuscript.

Declarations

The author does not have any conflict of interest. This is a
review and did not involve animals or humans.

Disclaimers: The author discloses the views expressed in the
article are her own and not an official position of the institution
or funding agency.

References

1. Fact sheet N’312 2015 [7/25/2015]. Available from: www.who.int/
diabetes.

2. Wood RJ, O’Neill EC. Resistance Training in Type II Diabetes Mellitus:
Impact on Areas of Metabolic Dysfunction in Skeletal Muscle and
Potential Impact on Bone. J Nutr Metab. 2012;2012:268197. doi:
10.1155/2012/268197.
3. Economic costs of diabetes in the US in 2012-2013 [06/25/2015].
Available from: www.professional.diabetes.org/news.
4. Andersen H, Nielsen S, Mogensen CE, Jakobsen J. Muscle strength in

Citation: Banu J (2016) Diabetes and Physical Activity. J Endocrinol Diab 3(1): 1-12. DOI: http://dx.doi.org/10.15226/23746890/3/1/00140

Page 5 of 12

Diabetes and Physical Activity

type 2 diabetes. Diabetes. 2004;53(6):1543-1548.

5. Andreassen CS, Jakobsen J, Andersen H. Muscle weakness:
a progressive late complication in diabetic distal symmetric
polyneuropathy. Diabetes. 2006;55(3):806-812.

6. Balducci S, Sacchetti M, Orlando G, Salvi L, Pugliese L, Salerno G, et al.
Correlates of muscle strength in diabetes: The study on the assessment
of determinants of muscle and bone strength abnormalities in
diabetes (SAMBA). Nutr Metab Cardiovasc Dis. 2014;24(1):18-26. doi:
10.1016/j.numecd.2013.04.010.
7. Andersen H, Poulsen PL, Mogensen CE, Jakobsen J. Isokinetic
muscle strength in long-term IDDM patients in relation to diabetic
complications. Diabetes. 1996;45(4):440-445.

8. Stenholm S, Harkanen T, Sainio P, Heliovaara M, Koskinen S. Longterm changes in handgrip strength in men and women--accounting
the effect of right censoring due to death. J Gerontol A Biol Sci Med
Sci. 2012;67(10):1068-1074. doi: 10.1093/gerona/ gls064.

9. Park SW, Goodpaster BH, Strotmeyer ES, de Rekeneire N, Harris TB,
Schwartz AV, et al. Decreased muscle strength and quality in older
adults with type 2 diabetes: the health, aging, and body composition
study. Diabetes. 2006;55(6):1813-1818.
10. TH IJ, Schaper NC, Melai T, Meijer K, Willems PJ, Savelberg HH.
Lower extremity muscle strength is reduced in people with type 2
diabetes, with and without polyneuropathy, and is associated with
impaired mobility and reduced quality of life. Diabetes Res Clin
Pract. 2012;95(3):345-351. doi: 10.1016/ j.diabres.2011.10.026.

11. Sacchetti M, Balducci S, Bazzucchi I, Carlucci F, Scotto di Palumbo A,
Haxhi J, et al. Neuromuscular dysfunction in diabetes: role of nerve
impairment and training status. Med Sci Sports Exerc. 2013;45(1):5259. doi: 10.1249/ MSS.0b013e318269f9bb.
12. Ijzerman TH, Schaper NC, Melai T, Blijham P, Meijer K, Willems PJ, et
al. Motor nerve decline does not underlie muscle weakness in type 2
diabetic neuropathy. Muscle Nerve. 2011;44(2):241-5. doi: 10.1002/
mus.22039.
13. Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R,
Kammerer C, et al. Accelerated loss of skeletal muscle strength in older
adults with type 2 diabetes: the health, aging, and body composition
study. Diabetes Care. 2007;30(6):1507-1512.
14. Wrobel JS, Najafi B. Diabetic foot biomechanics and gait dysfunction.
Journal J Diabetes Sci Technol. 2010 ;4(4):833-845.

15. Andreassen CS, Jakobsen J, Ringgaard S, Ejskjaer N, Andersen H.
Accelerated atrophy of lower leg and foot muscles--a follow-up study
of long-term diabetic polyneuropathy using magnetic resonance
imaging (MRI). Diabetologia. 2009;52(6):1182-91. doi: 10.1007/
s00125-009-1320-0.
16. Dolan NC, Liu K, Criqui MH, Greenland P, Guralnik JM, Chan C, et al.
Peripheral artery disease, diabetes, and reduced lower extremity
functioning. Diabetes Care. 25(1):113-120.
17. Stehno-Bittel L. Organ-based response to exercise in type 1 diabetes.
ISRN Endocrinol. 2012;2012:318194. doi: 10.5402/2012/318194.

18. Herrero P, Marin R, Fernandez Vega F, Gorostidi M, Riesgo A, Vazquez
J, et al. Renal function and cardiovascular risk in patients with essential
hypertension. The “FRESHA” study. Nefrologia. 2006;26(3):330-338.

19. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of
hemodynamic rather than metabolic factors in the pathogenesis of
diabetic glomerulopathy. Proc Natl Acad Sci USA. 1985;82(17):59635967.

Copyright:
© 2016 Banu
20. Evans N, Forsyth E. End-stage renal disease in people with type 2
diabetes: systemic manifestations and exercise implications. Phys
Ther. 2004;84(5):454-463.
21. American Diabetes Association [7/22/2015]. Available from: www.
diabetes.org/diabetes_basics/type 1.

22. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow
glucose removal rate and hyper insulinemia precede the development
of type II diabetes in the offspring of diabetic parents. Ann Intern Med.
1990;113(12):909-915.

23. Perseghin G, Ghosh S, Gerow K, Shulman GI. Metabolic defects in lean
nondiabetic offspring of NIDDM parents: a cross-sectional study.
Diabetes. 1997;46(6):1001-1009.
24. Jallut D, Golay A, Munger R, Frascarolo P, Schutz Y, Jequier E, et al.
Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up
study of glucose metabolism. Metabolism. 1990;39(10):1068-1075.

25. Ferrannini E, Gastaldelli A, Matsuda M, Miyazaki Y, Pettiti M, Glass
L, et al. Influence of ethnicity and familial diabetes on glucose
tolerance and insulin action: a physiological analysis. J Clin Endocrinol
Metab. 2003;88(7):3251-3257.

26. Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo RA. The metabolic
profile of NIDDM is fully established in glucose-tolerant offspring of
two Mexican-American NIDDM parents. Diabetes. 1992;41(12):15751586.
27. Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T,
Finlayson J, et al. Discordant effects of a chronic physiological increase
in plasma FFA on insulin signaling in healthy subjects with or without
a family history of type 2 diabetes. Am J Physiol Endocrinol Metab.
2004;287(3):E537-546.

28. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the
primary defect in type 2 diabetes. Diabetes Care. 2009;32 Suppl
2:S157-163. doi: 10.2337/ dc09-S302.

29. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle
attenuation determined by computed tomography is associated with
skeletal muscle lipid content. J Appl Physiol (1985). 2000;89(1):104110.
30. Cree MG, Newcomer BR, Katsanos CS, Sheffield-Moore M, Chinkes D,
Aarsland A, et al. Intramuscular and liver triglycerides are increased
in the elderly. J Clin Endocrinol Metab. 2004;89(8):3864-3871.
31. Garcia-Roves PM. Mitochondrial pathophysiology and type 2 diabetes
mellitus. Arch Physiol Biochem. 2011;117(3):177-187. doi: 10.3109/
13813455.2011.584538.

32. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance:
unravelling the mechanism. Lancet. 2010 26;375(9733):2267-277.
doi: 10.1016/ S0140-6736(10)60408-4.
33. Evans WJ. Exercise, nutrition and aging. J Nutr. 1992;122(3
Suppl):796-801.
34. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R.
Myostatin inhibits myoblast differentiation by down-regulating MyoD
expression. J Biol Chem. 2002;277(51):49831-49840.

35. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle
mass in mice by a new TGF-beta superfamily member. Nature.
1997;387(6628):83-90.

36. Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH, Jr, et
al. Myostatin inhibits cell proliferation and protein synthesis in C2C12
muscle cells. Am J Physiol Endocrinol Metab. 2001;280(2):E221-228.

Citation: Banu J (2016) Diabetes and Physical Activity. J Endocrinol Diab 3(1): 1-12. DOI: http://dx.doi.org/10.15226/23746890/3/1/00140

Page 6 of 12

Diabetes and Physical Activity

37. Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J, et al. Myostatin,
a negative regulator of muscle growth, functions by inhibiting
myoblast proliferation. J Biol Chem. 2000;275(51):40235-40243.

Copyright:
© 2016 Banu
myostatin reduces tumor necrosis factor alpha production and
protects liver against obesity-induced insulin resistance. Diabetes.
2009;58(5):1133-1143. doi: 10.2337/ db08-0245.

38. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass
DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting
myoblast differentiation and myotube size. Am J Physiol Cell Physiol.
2009;296(6):C1258-1270. doi: 10.1152/ ajpcell.00105.2009.

54. Smith GL, Doherty AP, Banks LM, Dutton J, Hanham LW, Christmas
TJ, et al. Dual X-ray absorptiometry detects disease- and treatmentrelated alterations of bone density in prostate cancer patients. Clin
Exp Metastasis. 2000;18(5):385-390.

40. Welle S, Bhatt K, Pinkert CA. Myofibrillar protein synthesis
in myostatin-deficient mice. Am J Physiol Endocrinol Metab.
2006;290(3):E409-415.

56. Larsen S, Ara I, Rabol R, Andersen JL, Boushel R, Dela F, et al. Are
substrate use during exercise and mitochondrial respiratory capacity
decreased in arm and leg muscle in type 2 diabetes? Diabetologia.
2009;52(7):1400-8. doi: 10.1007/ s00125-009-1353-4.

39. Matsakas A, Foster K, Otto A, Macharia R, Elashry MI, Feist S, et al.
Molecular, cellular and physiological investigation of myostatin
propeptide-mediated muscle growth in adult mice. Neuromuscul
Disord. 2009;19(7):489-499. doi: 10.1016/ j.nmd.2009.06.367.

41. Allen DL, Hittel DS, McPherron AC. Expression and function of myostatin
in obesity, diabetes, and exercise adaptation. Med Sci Sports Exerc.
2011;43(10):1828-835. doi: 10.1249/ MSS.0b013e3182178bb4.

42. Palsgaard J, Brons C, Friedrichsen M, Dominguez H, Jensen M,
Storgaard H, et al. Gene expression in skeletal muscle biopsies from
people with type 2 diabetes and relatives: differential regulation of
insulin signaling pathways. PLoS One. 2009;4(8):e6575. doi: 10.1371/
journal.pone.0006575.
43. Moller DE. Potential role of TNF-alpha in the pathogenesis of
insulin resistance and type 2 diabetes. Trends Endocrinol Metab.
2000;11(6):212-217.
44. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, et
al. Myostatin mutation associated with gross muscle hypertrophy in a
child. N Engl J Med. 2004;350(26):2682-2688.

45. Yang J, Ratovitski T, Brady JP, Solomon MB, Wells KD, Wall RJ.
Expression of myostatin pro domain results in muscular transgenic
mice. Mol Reprod Dev. 2001;60(3):351-361.
46. Zhu X, Hadhazy M, Wehling M, Tidball JG, McNally EM. Dominant
negative myostatin produces hypertrophy without hyperplasia in
muscle. FEBS Lett. 2000;474(1):71-75.

47. Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal
muscle in non-insulin-dependent diabetes mellitus. J Clin Invest.
1994;94(6):2349-2356.
48. Malenfant P, Joanisse DR, Theriault R, Goodpaster BH, Kelley DE,
Simoneau JA. Fat content in individual muscle fibers of lean and obese
subjects. Int J Obes Relat Metab Disord. 2001;25(9):1316-1321.
49. Goodpaster BH, Thaete FL, Kelley DE. Thigh adipose tissue distribution
is associated with insulin resistance in obesity and in type 2 diabetes
mellitus. Am J Clin Nutr. 2000;71(4):885-892.

50. Rector RS, Uptergrove GM, Borengasser SJ, Mikus CR, Morris EM,
Naples SP, et al. Changes in skeletal muscle mitochondria in response
to the development of type 2 diabetes or prevention by daily wheel
running in hyperphagic OLETF rats. Am J Physiol Endocrinol Metab.
2010;298(6):E1179-1187. doi: 10.1152/ ajpendo.00703.2009.
51. Vogel T, Brechat PH, Lepretre PM, Kaltenbach G, Berthel M,
Lonsdorfer J. Health benefits of physical activity in older patients:
a review. Int J Clin Pract. 2009;63(2):303-20. doi: 10.1111/ j.17421241.2008.01957.x.

52. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of
chronic diseases. Compr Physiol. 2012 ;2(2):1143-211. doi: 10.1002/
cphy.c110025.
53. Wilkes JJ, Lloyd DJ, Gekakis N. Loss-of-function mutation in

55. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of
mitochondria in human skeletal muscle in type 2 diabetes. Diabetes.
2002;51(10):2944-2950.

57. Ritov VB, Menshikova EV, Azuma K, Wood R, Toledo FG, Goodpaster
BH, et al. Deficiency of electron transport chain in human skeletal
muscle mitochondria in type 2 diabetes mellitus and obesity. Am
J Physiol Endocrinol Metab. 2010;298(1):E49-58. doi: 10.1152/
ajpendo.00317.2009.
58. Schmitz-Peiffer C. Protein kinase C and lipid-induced insulin resistance
in skeletal muscle. Ann N Y Acad Sci. 2002;967:146-157.
59. Ashok BT, Ali R. The aging paradox: free radical theory of aging. Exp
Gerontol. 1999;34(3):293-303.

60. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free
radicals and antioxidants in normal physiological functions and
human disease. Int J Biochem Cell Biol. 2007;39(1):44-84.
61. Nobili V, de Ville de Goyet J. Pediatric post-transplant metabolic
syndrome: new clouds on the horizon. Pediatr Transplant.
2013;17(3):216-223. doi: 10.1111/ petr.12065.

62. Vincent HK, Innes KE, Vincent KR. Oxidative stress and potential
interventions to reduce oxidative stress in overweight and obesity.
Diabetes Obes Metab. 2007;9(6):813-839.

63. Kurohane Kaneko Y, Ishikawa T. Dual role of nitric oxide in pancreatic
beta-cells. J Pharmacol Sci. 2013;123(4):295-300.
64. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms
of pancreatic beta-cell death in type 1 and type 2 diabetes: many
differences, few similarities. Diabetes. 2005;54 Suppl 2:S97-107.

65. Noguchi A, Takada M, Nakayama K, Ishikawa T. cGMP-independent
anti-apoptotic effect of nitric oxide on thapsigargin-induced apoptosis
in the pancreatic beta-cell line INS-1. Life Sci. 2008;83(25-26):865-70.
doi: 10.1016/ j.lfs.2008.10.002.
66. Mosen H, Ostenson CG, Lundquist I, Alm P, Henningsson R, JimenezFeltstrom J, et al. Impaired glucose-stimulated insulin secretion
in the GK rat is associated with abnormalities in islet nitric oxide
production. Regul Pept. 2008;151(1-3):139-146. doi: 10.1016/
j.regpep.2008.07.002.
67. Kaliman P, Canicio J, Testar X, Palacin M, Zorzano A. Insulin-like growth
factor-II, phosphatidylinositol 3-kinase, nuclear factor-kappaB and
inducible nitric-oxide synthase define a common myogenic signaling
pathway. J Biol Chem. 1999;274(25):17437-17444.

68. Prats-Puig A, Ortega FJ, Mercader JM, Moreno-Navarrete JM, Moreno
M, Bonet N, et al. Changes in circulating microRNAs are associated
with childhood obesity. J Clin Endocrinol Metab. 2013;98(10):E16551660. doi: 10.1210/ jc.2013-1496.
69. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M,
et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature.

Citation: Banu J (2016) Diabetes and Physical Activity. J Endocrinol Diab 3(1): 1-12. DOI: http://dx.doi.org/10.15226/23746890/3/1/00140

Page 7 of 12

Diabetes and Physical Activity

2011;474(7353):649-653. doi: 10.1038/ nature10112.

70. Zhu H, Shyh-Chang N, Segre AV, Shinoda G, Shah SP, Einhorn WS,
et al. The Lin28/let-7 axis regulates glucose metabolism. Cell.
2011;147(1):81-94. doi: 10.1016/ j.cell.2011.08.033.

71. Jiang LQ, Franck N, Egan B, Sjögren RJ, Katayama M, Duque-Guimaraes
D, et al. Autocrine role of interleukin-13 on skeletal muscle glucose
metabolism in type 2 diabetic patients involves microRNA let-7. Am
J Physiol Endocrinol Metab. 2013;305(11):E1359-66. doi: 10.1152/
ajpendo.00236.2013.
72. Gallagher IJ, Scheele C, Keller P, Nielsen AR, Remenyi J, Fischer CP, et
al. Integration of microRNA changes in vivo identifies novel molecular
features of muscle insulin resistance in type 2 diabetes. Genome Med.
2010;2(2):9. doi: 10.1186/gm130.

73. Patti A, Gennari L, Merlotti D, Dotta F, Nuti R. Endocrine actions
of osteocalcin. Int J Endocrinol. 2013;2013:846480. doi:
10.1155/2013/846480.
74. Bulló M, Moreno-Navarrete JM, Fernández-Real JM, Salas-Salvadó J.
Total and undercarboxylated osteocalcin predict changes in insulin
sensitivity and β cell function in elderly men at high cardiovascular risk.
Am J Clin Nutr. 2012;95(1):249-55. doi: 10.3945/ajcn.111.016642.

75. Fernández-Real JM, Izquierdo M, Ortega F, Gorostiaga E, GómezAmbrosi J, Moreno-Navarrete JM, et al. The relationship of serum
osteocalcin concentration to insulin secretion, sensitivity, and disposal
with hypocaloric diet and resistance training. J Clin Endocrinol Metab.
2009;94(1):237-45. doi: 10.1210/jc.2008-0270.
76. Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent
injections of osteocalcin improve glucose metabolism and prevent
type 2 diabetes in mice. Bone. 2012;50(2):568-75. doi: 10.1016/j.
bone.2011.04.017.

77. Brazeau AS, Rabasa-Lhoret R, Strychar I, Mircescu H. Barriers to
physical activity among patients with type 1 diabetes. Diabetes Care.
2008;31(11):2108-9. doi: 10.2337/dc08-0720.

78. Vagetti GC, Barbosa Filho VC, Moreira NB, Oliveira Vd, Mazzardo O,
Campos Wd. Association between physical activity and quality of life
in the elderly: a systematic review, 2000-2012. Rev Bras Psiquiatr.
2014;36(1):76-88.
79. LeBrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM,
Brown TA. Myostatin inhibition enhances the effects of exercise on
performance and metabolic outcomes in aged mice. J Gerontol A Biol
Sci Med Sci. 2009;64(9):940-8. doi: 10.1093/gerona/glp068.
80. Bishop FK, Maahs DM, Snell-Bergeon JK, Ogden LG, Kinney GL,
Rewers M. Lifestyle risk factors for atherosclerosis in adults
with type 1 diabetes. Diab Vasc Dis Res. 2009;6(4):269-75. doi:
10.1177/1479164109346359.

81. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, et al.
Mitochondrial overload and incomplete fatty acid oxidation contribute
to skeletal muscle insulin resistance. Cell Metab. 2008;7(1):45-56. doi:
10.1016/j.cmet.2007.10.013.

82. Thyfault JP, Cree MG, Tapscott EB, Bell JA, Koves TR, Ilkayeva O, et al.
Metabolic profiling of muscle contraction in lean compared with obese
rodents. Am J Physiol Regul Integr Comp Physiol. 2010;299(3):R92634. doi: 10.1152/ajpregu.00093.2010.

83. Alibegovic AC, Sonne MP, Højbjerre L, Bork-Jensen J, Jacobsen S,
Nilsson E, et al. Insulin resistance induced by physical inactivity is
associated with multiple transcriptional changes in skeletal muscle
in young men. Am J Physiol Endocrinol Metab. 2010;299(5):E752-63.
doi: 10.1152/ajpendo.00590.2009.

Copyright:
© 2016 Banu
84. Fleg JL, Morrell CH, Bos AG, Brant LJ, Talbot LA, Wright JG, et al.
Accelerated longitudinal decline of aerobic capacity in healthy older
adults. Circulation. 2005;112(5):674-82.
85. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et
al. Risk factors for 5-year mortality in older adults: the Cardiovascular
Health Study. JAMA. 1998;279(8):585-92.
86. Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela
O, Menotti A, et al. Mediterranean diet, lifestyle factors, and 10-year
mortality in elderly European men and women: the HALE project.
JAMA. 2004;292(12):1433-9.
87. Sundquist K, Qvist J, Sundquist J, Johansson SE. Frequent and
occasional physical activity in the elderly: a 12-year follow-up study
of mortality. Am J Prev Med. 2004;27(1):22-7.

88. Hakim AA, Petrovitch H, Burchfiel CM, Ross GW, Rodriguez BL, White
LR, et al. Effects of walking on mortality among nonsmoking retired
men. N Engl J Med. 1998;338(2):94-9.
89. Bijnen FC, Caspersen CJ, Feskens EJ, Saris WH, Mosterd WL, Kromhout
D. Physical activity and 10-year mortality from cardiovascular
diseases and all causes: The Zutphen Elderly Study. Arch Intern Med.
1998;158(14):1499-505.

90. Franco OH, de Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder
W. Effects of physical activity on life expectancy with cardiovascular
disease. Arch Intern Med. 2005;165(20):2355-60.
91. Rolland Y, Lauwers-Cances V, Cesari M, Vellas B, Pahor M, Grandjean
H. Physical performance measures as predictors of mortality in a
cohort of community-dwelling older French women. Eur J Epidemiol.
2006;21(2):113-22.

92. Benetos A, Thomas F, Bean KE, Pannier B, Guize L. Role of
modifiable risk factors in life expectancy in the elderly. J Hypertens.
2005;23(10):1803-8.
93. Landi F, Cesari M, Onder G, Lattanzio F, Gravina EM, Bernabei R.
Physical activity and mortality in frail, community-living elderly
patients. J Gerontol A Biol Sci Med Sci. 2004;59(8):833-7.

94. Chakravarty EF, Hubert HB, Lingala VB, Fries JF. Reduced disability
and mortality among aging runners: a 21-year longitudinal
study. Arch Intern Med. 2008;168(15):1638-46. doi: 10.1001/
archinte.168.15.1638.
95. Wannamethee SG, Shaper AG, Walker M. Physical activity and
mortality in older men with diagnosed coronary heart disease.
Circulation. 2000;102(12):1358-63.
96. Hakim AA, Curb JD, Petrovitch H, Rodriguez BL, Yano K, Ross GW, et
al. Effects of walking on coronary heart disease in elderly men: the
Honolulu Heart Program. Circulation. 1999;100(1):9-13.
97. Petrella RJ, Lattanzio CN, Demeray A, Varallo V, Blore R. Can adoption of
regular exercise later in life prevent metabolic risk for cardiovascular
disease? Diabetes Care. 2005;28(3):694-701.
98. Halverstadt A, Phares DA, Wilund KR, Goldberg AP, Hagberg
JM. Endurance exercise training raises high-density lipoprotein
cholesterol and lowers small low-density lipoprotein and very lowdensity lipoprotein independent of body fat phenotypes in older men
and women. Metabolism. 2007;56(4):444-50.
99. Brooks GA, Fahey TD, White TP. Exercise physiology: Human
bioenergetics and its application. Mountain View, CA: Mayfield
Publishing Co; 1995.

100. Siscovick DS, LaPorte RE, Newman JM. The disease-specific benefits
and risks of physical activity and exercise. Public Health Rep.

Citation: Banu J (2016) Diabetes and Physical Activity. J Endocrinol Diab 3(1): 1-12. DOI: http://dx.doi.org/10.15226/23746890/3/1/00140

Page 8 of 12

Diabetes and Physical Activity

1985;100(2):180-8.

101. McGregor RA, Poppitt SD, Cameron-Smith D. Role of microRNAs
in the age-related changes in skeletal muscle and diet or exercise
interventions to promote healthy aging in humans. Ageing Res Rev.
2014;17:25-33. doi: 10.1016/j.arr.2014.05.001.
102. Wang Q, Jin T. The role of insulin signaling in the development of
β-cell dysfunction and diabetes. Islets. 2009;1(2):95-101. doi:
10.4161/isl.1.2.9263.

103. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et
al. Physical activity and public health: updated recommendation
for adults from the American College of Sports Medicine and the
American Heart Association. Med Sci Sports Exerc. 2007;39(8):142334.
104. Holloszy JO. Adaptations of muscular tissue to training. Prog
Cardiovasc Dis. 1976;18(6):445-58.
105. Holloszy JO, Booth FW. Biochemical adaptations to endurance
exercise in muscle. Annu Rev Physiol. 1976;38:273-91.

106. Ivy JL, Holloszy JO. Persistent increase in glucose uptake by rat
skeletal muscle following exercise. Am J Physiol. 1981;241(5):C2003.
107. Heath GW, Gavin JR 3rd, Hinderliter JM, Hagberg JM, Bloomfield
SA, Holloszy JO. Effects of exercise and lack of exercise on glucose
tolerance and insulin sensitivity. J Appl Physiol Respir Environ Exerc
Physiol. 1983;55(2):512-7.
108. Mikines KJ, Sonne B, Farrell PA, Tronier B, Galbo H. Effect of physical
exercise on sensitivity and responsiveness to insulin in humans. Am
J Physiol. 1988;254(3 Pt 1):E248-59.

109. Richter EA, Garetto LP, Goodman MN, Ruderman NB. Muscle glucose
metabolism following exercise in the rat: increased sensitivity to
insulin. J Clin Invest. 1982;69(4):785-93.

110. Cox JH, Cortright RN, Dohm GL, Houmard JA. Effect of aging on
response to exercise training in humans: skeletal muscle GLUT-4
and insulin sensitivity. J Appl Physiol (1985). 1999;86(6):2019-25.
111. Evans EM, Racette SB, Peterson LR, Villareal DT, Greiwe JS, Holloszy
JO. Aerobic power and insulin action improve in response to
endurance exercise training in healthy 77-87 yr olds. J Appl Physiol
(1985). 2005;98(1):40-5.

112. DiPietro L, Dziura J, Yeckel CW, Neufer PD. Exercise and improved
insulin sensitivity in older women: evidence of the enduring benefits
of higher intensity training. J Appl Physiol (1985). 2006;100(1):1429.
113. Yki-Järvinen H, DeFronzo RA, Koivisto VA. Normalization of insulin
sensitivity in type I diabetic subjects by physical training during
insulin pump therapy. Diabetes Care. 1984;7(6):520-7.

114. Richter EA, Nielsen JN, Jørgensen SB, Frøsig C, Birk JB, Wojtaszewski
JF. Exercise signalling to glucose transport in skeletal muscle. Proc
Nutr Soc. 2004;63(2):211-6.
115. Rose AJ, Richter EA. Skeletal muscle glucose uptake during exercise:
how is it regulated? Physiology (Bethesda). 2005;20:260-70.
116. Musi N, Fujii N, Hirshman MF, Ekberg I, Fröberg S, Ljungqvist
O, et al. AMP-activated protein kinase (AMPK) is activated in
muscle of subjects with type 2 diabetes during exercise. Diabetes.
2001;50(5):921-7.
117. Brooks N, Layne JE, Gordon PL, Roubenoff R, Nelson ME, CastanedaSceppa C. Strength training improves muscle quality and insulin

Copyright:
© 2016 Banu
sensitivity in Hispanic older adults with type 2 diabetes. Int J Med
Sci. 2006;4(1):19-27.

118. Kobzik L, Stringer B, Balligand JL, Reid MB, Stamler JS. Endothelial
type nitric oxide synthase in skeletal muscle fibers: mitochondrial
relationships. Biochem Biophys Res Commun. 1995;211(2):375-81.
119. Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle.
Physiol Rev. 2001;81(1):209-237.

120. Boczkowski J, Lanone S, Ungureanu-Longrois D, Danialou G, Fournier
T, Aubier M. Induction of diaphragmatic nitric oxide synthase after
endotoxin administration in rats: role on diaphragmatic contractile
dysfunction. J Clin Invest. 1996;98(7):1550-9.
121. El Dwairi Q, Guo Y, Comtois A, Zhu E, Greenwood MT, Bredt DS, et al.
Ontogenesis of nitric oxide synthases in the ventilatory muscles. Am
J Respir Cell Mol Biol. 1998;18(6):844-52.

122. Tidball JG, Lavergne E, Lau KS, Spencer MJ, Stull JT, Wehling M.
Mechanical loading regulates NOS expression and activity in
developing and adult skeletal muscle. Am J Physiol. 1998;275(1 Pt
1):C260-6.
123. Wehling M, Stull JT, McCabe TJ, Tidball JG. Sparing of mdx extraocular
muscles from dystrophic pathology is not attributable to normalized
concentration or distribution of neuronal nitric oxide synthase.
Neuromuscul Disord. 1998;8(1):22-9.

124. Balon TW, Nadler JL. Evidence that nitric oxide increases glucose
transport in skeletal muscle. J Appl Physiol (1985). 1997;82(1):35963.
125. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise
in dogs increases coronary vascular nitric oxide production and
endothelial cell nitric oxide synthase gene expression. Circ Res.
1994;74(2):349-53.

126. Wang XH. MicroRNA in myogenesis and muscle atrophy. Curr
Opin Clin Nutr Metab Care. 2013;16(3):258-66. doi: 10.1097/
MCO.0b013e32835f81b9.
127. Drummond MJ, McCarthy JJ, Sinha M, Spratt HM, Volpi E, Esser KA,
et al. Aging and microRNA expression in human skeletal muscle:
a microarray and bioinformatics analysis. Physiol Genomics.
2011;43(10):595-603. doi: 10.1152/physiolgenomics.00148.2010.
128. Drummond MJ, McCarthy JJ, Fry CS, Esser KA, Rasmussen BB.
Aging differentially affects human skeletal muscle microRNA
expression at rest and after an anabolic stimulus of resistance
exercise and essential amino acids. Am J Physiol Endocrinol Metab.
2008;295(6):E1333-40. doi: 10.1152/ajpendo.90562.2008.

129. Olivieri F, Spazzafumo L, Santini G, Lazzarini R, Albertini MC, Rippo
MR, et al. Age-related differences in the expression of circulating
microRNAs: miR-21 as a new circulating marker of inflammaging.
Mech Ageing Dev. 2012;133(11-12):675-85. doi: 10.1016/j.
mad.2012.09.004.
130. Hamrick MW, Herberg S, Arounleut P, He HZ, Shiver A, Qi RQ,
et al. The adipokine leptin increases skeletal muscle mass and
significantly alters skeletal muscle miRNA expression profile in aged
mice. Biochem Biophys Res Commun. 2010;400(3):379-83. doi:
10.1016/j.bbrc.2010.08.079.
131. Mercken EM, Majounie E, Ding J, Guo R, Kim J, Bernier M, et al.
Age-associated miRNA alterations in skeletal muscle from rhesus
monkeys reversed by caloric restriction. Aging (Albany NY).
2013;5(9):692-703.
132. Safdar A, Abadi A, Akhtar M, Hettinga BP, Tarnopolsky MA. miRNA

Citation: Banu J (2016) Diabetes and Physical Activity. J Endocrinol Diab 3(1): 1-12. DOI: http://dx.doi.org/10.15226/23746890/3/1/00140

Page 9 of 12

Diabetes and Physical Activity

Copyright:
© 2016 Banu

in the regulation of skeletal muscle adaptation to acute endurance
exercise in C57Bl/6J male mice. PLoS One. 2009;4(5):e5610. doi:
10.1371/journal.pone.0005610 .

147. Seals DR, Hagberg JM, Hurley BF, Ehsani AA, Holloszy JO. Effects of
endurance training on glucose tolerance and plasma lipid levels in
older men and women. JAMA. 1984;252(5):645-9.

134. McCarthy JJ, Esser KA, Andrade FH. MicroRNA-206 is overexpressed
in the diaphragm but not the hindlimb muscle of mdx mouse. Am J
Physiol Cell Physiol. 2007;293(1):C451-7.

149. Rogers MA, King DS, Hagberg JM, Ehsani AA, Holloszy JO. Effect of 10
days of physical inactivity on glucose tolerance in master athletes. J
Appl Physiol (1985). 1990;68(5):1833-7.

133. Nielsen S, Scheele C, Yfanti C, Akerström T, Nielsen AR, Pedersen
BK, et al. Muscle specific microRNAs are regulated by endurance
exercise in human skeletal muscle. J Physiol. 2010;588(Pt 20):402937. doi: 10.1113/jphysiol.2010.189860.

135. Davidsen PK, Gallagher IJ, Hartman JW, Tarnopolsky MA, Dela
F, Helge JW, et al. High responders to resistance exercise training
demonstrate differential regulation of skeletal muscle microRNA
expression. J Appl Physiol (1985). 2011;110(2):309-17. doi:
10.1152/japplphysiol.00901.2010.
136. Mueller M, Breil FA, Lurman G, Klossner S, Flück M, Billeter R, et
al. Different molecular and structural adaptations with eccentric
and conventional strength training in elderly men and women.
Gerontology. 2011;57(6):528-38. doi: 10.1159/000323267.
137. Rattigan S, Wallis MG, Youd JM, Clark MG. Exercise training improves
insulin-mediated capillary recruitment in association with glucose
uptake in rat hindlimb. Diabetes. 2001;50(12):2659-65.

138. Gulve EA. Exercise and glycemic control in diabetes: benefits,
challenges, and adjustments to pharmacotherapy. Phys Ther.
2008;88(11):1297-321. doi: 10.2522/ptj.20080114.

139. Huang HH, Farmer K, Windscheffel J, Yost K, Power M, Wright DE, et al.
Exercise increases insulin content and basal secretion in pancreatic
islets in type 1 diabetic mice. Exp Diabetes Res. 2011;2011:481427.
doi: 10.1155/2011/481427.
140. Coskun O, Ocakci A, Bayraktaroglu T, Kanter M. Exercise training
prevents and protects streptozotocin-induced oxidative stress
and beta-cell damage in rat pancreas. Tohoku J Exp Med.
2004;203(3):145-54.
141. Krause Mda S, de Bittencourt PI Jr. Type 1 diabetes: can exercise
impair the autoimmune event? The L-arginine/glutamine coupling
hypothesis. Cell Biochem Funct. 2008;26(4):406-33. doi: 10.1002/
cbf.1470.

142. Frosig C, Richter EA. Improved insulin sensitivity after exercise:
focus on insulin signaling. Obesity (Silver Spring). 2009;S15-20. doi:
10.1038/oby.2009.383.
143. Holmes B, Dohm GL. Regulation of GLUT4 gene expression during
exercise. Med Sci Sports Exerc. 2004;36(7):1202-6.

144. Salem MA, Aboelasrar MA, Elbarbary NS, Elhilaly RA, Refaat YM. Is
exercise a therapeutic tool for improvement of cardiovascular risk
factors in adolescents with type 1 diabetes mellitus? A randomised
controlled trial. Diabetol Metab Syndr. 2010;2(1):47. doi:
10.1186/1758-5996-2-47.
145. Kluding PM, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J, et
al. The effect of exercise on neuropathic symptoms, nerve function,
and cutaneous innervation in people with diabetic peripheral
neuropathy. J Diabetes Complications. 2012;26(5):424-9. doi:
10.1016/j.jdiacomp.2012.05.007.
146. Garcia-Garcia F, Kumareswaran K, Hovorka R, Hernando ME.
Quantifying the acute changes in glucose with exercise in type
1 diabetes: a systematic review and meta-analysis. Sports Med.
2015;45(4):587-99. doi: 10.1007/s40279-015-0302-2.

148. Hittel DS, Axelson M, Sarna N, Shearer J, Huffman KM, Kraus WE.
Myostatin decreases with aerobic exercise and associates with
insulin resistance. Med Sci Sports Exerc. 2010;42(11):2023-9. doi:
10.1249/MSS.0b013e3181e0b9a8.

150. Kirwan JP, Solomon TP, Wojta DM, Staten MA, Holloszy JO. Effects of
7 days of exercise training on insulin sensitivity and responsiveness
in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab.
2009;297(1):E151-6. doi: 10.1152/ajpendo.00210.2009.
151. Boor P, Celec P, Behuliak M, Grancic P, Kebis A, Kukan M, et al. Regular
moderate exercise reduces advanced glycation and ameliorates
early diabetic nephropathy in obese Zucker rats. Metabolism.
200;58(11):1669-77. doi: 10.1016/j.metabol.2009.05.025.
152. Albright AL, Mahan JD, Ward KM, Sherman WM, Roehrig KL, Kirby
TE. Diabetic nephropathy in an aerobically trained rat model of
diabetes. Med Sci Sports Exerc. 1995;27(9):1270-7.

153. Kutlu M, Naziroglu M, Simsek H, Yilmaz T, Sahap Kukner A. Moderate
exercise combined with dietary vitamins C and E counteracts
oxidative stress in the kidney and lens of streptozotocin-induced
diabetic-rat. Int J Vitam Nutr Res. 2005;75(1):71-80.

154. Peng CC, Chen KC, Hsieh CL, Peng RY. Swimming exercise
prevents fibrogenesis in chronic kidney disease by inhibiting the
myofibroblast transdifferentiation. PLoS One. 2012;7(6):e37388.
doi: 10.1371/journal.pone.0037388.
155. Loganathan R, Bilgen M, Al-Hafez B, Zhero SV, Alenezy MD, Smirnova
IV. Exercise training improves cardiac performance in diabetes: in
vivo demonstration with quantitative cine-MRI analyses. J Appl
Physiol (1985). 2007;102(2):665-72.

156. Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise
on glycemic control and body mass in type 2 diabetes mellitus: a
meta-analysis of controlled clinical trials. JAMA. 2001;286(10):121827.
157. Dela F, Ploug T, Handberg A, Petersen LN, Larsen JJ, Mikines KJ, et
al. Physical training increases muscle GLUT4 protein and mRNA in
patients with NIDDM. Diabetes. 1994;43(7):862-5.

158. Hughes VA, Fiatarone MA, Fielding RA, Kahn BB, Ferrara CM,
Shepherd P, et al. Exercise increases muscle GLUT-4 levels and
insulin action in subjects with impaired glucose tolerance. Am J
Physiol. 1993;264(6 Pt 1):E855-62.
159. Kirwan JP, Kohrt WM, Wojta DM, Bourey RE, Holloszy JO. Endurance
exercise training reduces glucose-stimulated insulin levels in 60- to
70-year-old men and women. J Gerontol. 1993;48(3):M84-90.
160. Harber MP, Crane JD, Dickinson JM, Jemiolo B, Raue U, Trappe TA,
et al. Protein synthesis and the expression of growth-related genes
are altered by running in human vastus lateralis and soleus muscles.
Am J Physiol Regul Integr Comp Physiol. 2009;296(3):R708-14. doi:
10.1152/ajpregu.90906.2008.

161. Louis E, Raue U, Yang Y, Jemiolo B, Trappe S. Time course of
proteolytic, cytokine, and myostatin gene expression after
acute exercise in human skeletal muscle. J Appl Physiol (1985).
2007;103(5):1744-51.

Citation: Banu J (2016) Diabetes and Physical Activity. J Endocrinol Diab 3(1): 1-12. DOI: http://dx.doi.org/10.15226/2374- Page 10 of 12
6890/3/1/00140

Diabetes and Physical Activity

162. Hennebry A, Berry C, Siriett V, O’Callaghan P, Chau L, Watson T, et
al. Myostatin regulates fiber-type composition of skeletal muscle
by regulating MEF2 and MyoD gene expression. Am J Physiol Cell
Physiol. 2009;296(3):C525-34. doi: 10.1152/ajpcell.00259.2007.

163. Girgenrath S, Song K, Whittemore LA. Loss of myostatin expression
alters fiber-type distribution and expression of myosin heavy chain
isoforms in slow- and fast-type skeletal muscle. Muscle Nerve.
2005;31(1):34-40.
164. Hulmi JJ, Ahtiainen JP, Kaasalainen T, Pollanen E, Hakkinen K, Alen
M, et al. Postexercise myostatin and activin IIb mRNA levels: effects
of strength training. Med Sci Sports Exerc. 2007;39(2):289-97.
165. Raue U, Slivka D, Jemiolo B, Hollon C, Trappe S. Myogenic gene
expression at rest and after a bout of resistance exercise in young
(18-30 yr) and old (80-89 yr) women. J Appl Physiol (1985).
2006;101(1):53-9.

166. Roth SM, Martel GF, Ferrell RE, Metter EJ, Hurley BF, Rogers MA.
Myostatin gene expression is reduced in humans with heavyresistance strength training: a brief communication. Exp Biol Med
(Maywood). 2003;228(6):706-9.
167. Kim JS, Cross JM, Bamman MM. Impact of resistance loading on
myostatin expression and cell cycle regulation in young and older men
and women. Am J Physiol Endocrinol Metab. 2005;288(6):E1110-9.

168. Kim JS, Petrella JK, Cross JM, Bamman MM. Load-mediated
downregulation of myostatin mRNA is not sufficient to promote
myofiber hypertrophy in humans: a cluster analysis. J Appl Physiol
(1985). 2007;103(5):1488-95.

169. Saremi A, Gharakhanloo R, Sharghi S, Gharaati MR, Larijani B,
Omidfar K. Effects of oral creatine and resistance training on serum
myostatin and GASP-1. Mol Cell Endocrinol. 2010;317(1-2):25-30.
doi: 10.1016/j.mce.2009.12.019.
170. Walker KS, Kambadur R, Sharma M, Smith HK. Resistance training
alters plasma myostatin but not IGF-1 in healthy men. Med Sci
Sports Exerc. 2004;36(5):787-93.
171. Coffey VG, Shield A, Canny BJ, Carey KA, Cameron-Smith D, Hawley
JA. Interaction of contractile activity and training history on mRNA
abundance in skeletal muscle from trained athletes. Am J Physiol
Endocrinol Metab. 2006;290(5):E849-55.

172. Willoughby DS. Effects of heavy resistance training on myostatin
mRNA and protein expression. Med Sci Sports Exerc. 2004;36(4):57482.
173. Irvine C, Taylor NF. Progressive resistance exercise improves
glycaemic control in people with type 2 diabetes mellitus: a
systematic review. Aust J Physiother. 2009;55(4):237-46.
174. Herriott MT, Colberg SR, Parson HK, Nunnold T, Vinik AI. Effects of 8
weeks of flexibility and resistance training in older adults with type
2 diabetes. Diabetes Care. 2004;27(12):2988-9.

175. Ibanez J, Izquierdo M, Arguelles I, Forga L, Larrion JL, Garcia-Unciti
M, et al. Twice-weekly progressive resistance training decreases
abdominal fat and improves insulin sensitivity in older men with
type 2 diabetes. Diabetes Care. 2005;28(3):662-7.

176. Gordon BA, Benson AC, Bird SR, Fraser SF. Resistance training
improves metabolic health in type 2 diabetes: a systematic review.
Diabetes Res Clin Pract. 2009;83(2):157-75. doi: 10.1016/j.
diabres.2008.11.024.
177. Tresierras MA, Balady GJ. Resistance training in the treatment
of diabetes and obesity: mechanisms and outcomes. J

Copyright:
© 2016 Banu
Cardiopulm Rehabil Prev. 2009;29(2):67-75. doi: 10.1097/
HCR.0b013e318199ff69.

178. Ishii T, Yamakita T, Sato T, Tanaka S, Fujii S. Resistance training
improves insulin sensitivity in NIDDM subjects without altering
maximal oxygen uptake. Diabetes Care. 1998;21(8):1353-5.

179. Holten MK, Zacho M, Gaster M, Juel C, Wojtaszewski JF, Dela F.
Strength training increases insulin-mediated glucose uptake, GLUT4
content, and insulin signaling in skeletal muscle in patients with
type 2 diabetes. Diabetes. 2004;53(2):294-305.

180. Praet SF, Jonkers RA, Schep G, Stehouwer CD, Kuipers H, Keizer HA,
et al. Longstanding, insulin-treated type 2 diabetes patients with
complications respond well to short-term resistance and interval
exercise training. Eur J Endocrinol. 2008;158(2):163-72. doi:
10.1530/EJE-07-0169.
181. Balakrishnan VS, Rao M, Menon V, Gordon PL, Pilichowska M,
Castaneda F, et al. Resistance training increases muscle mitochondrial
biogenesis in patients with chronic kidney disease. Clin J Am Soc
Nephrol. 2010;5(6):996-1002. doi: 10.2215/CJN.09141209.
182. Tarnopolsky MA. Mitochondrial DNA shifting in older adults
following resistance exercise training. Appl Physiol Nutr Metab.
2009;34(3):348-54. doi: 10.1139/H09-022.

183. Luthi JM, Howald H, Claassen H, Rosler K, Vock P, Hoppeler H.
Structural changes in skeletal muscle tissue with heavy-resistance
exercise. Int J Sports Med. 1986;7(3):123-7.
184. MacDougall JD, Sale DG, Moroz JR, Elder GC, Sutton JR, Howald H.
Mitochondrial volume density in human skeletal muscle following
heavy resistance training. Med Sci Sports. 1979;11(2):164-6.

185. Pivovarov JA, Taplin CE, Riddell MC. Current perspectives on
physical activity and exercise for youth with diabetes. Pediatr
Diabetes. 2015;16(4):242-55. doi: 10.1111/pedi.12272.
186. Mulvaney SA, Hood KK, Schlundt DG, Osborn CY, Johnson KB,
Rothman RL, et al. Development and initial validation of the barriers
to diabetes adherence measure for adolescents. Diabetes Res Clin
Pract. 2011;94(1):77-83. doi: 10.1016/j.diabres.2011.06.010.

187. Zabinski MF, Saelens BE, Stein RI, Hayden-Wade HA, Wilfley DE.
Overweight children’s barriers to and support for physical activity.
Obes Res. 2003;11(2):238-46.
188. Robertson K AP, Riddell MC, Scheiner G, Hanas R. Exercise in
children and adolescents with diabetes. Pediatr Diabetes. 2009;10
Suppl 12:154-68. doi: 10.1111/j.1399-5448.2009.00567.x.
189. Patton SR, Dolan LM, Henry R, Powers SW. Parental fear of
hypoglycemia: young children treated with continuous subcutaneous
insulin infusion. Pediatr Diabetes. 2007;8(6):362-8.
190. Francescato MP, Geat M, Fusi S, Stupar G, Noacco C, Cattin L.
Carbohydrate requirement and insulin concentration during
moderate exercise in type 1 diabetic patients. Metabolism.
2004;53(9):1126-30.

191. Adolfsson P, Nilsson S, Albertsson-Wikland K, Lindblad B.
Hormonal response during physical exercise of different intensities
in adolescents with type 1 diabetes and healthy controls.
Pediatr Diabetes. 2012;13(8):587-96. doi: 10.1111/j.13995448.2012.00889.x.
192. Na HK, Oliynyk S. Effects of physical activity on cancer prevention.
Ann N Y Acad Sci. 2011;1229:176-83. doi: 10.1111/j.17496632.2011.06105.x.
193. Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical activity of

Citation: Banu J (2016) Diabetes and Physical Activity. J Endocrinol Diab 3(1): 1-12. DOI: http://dx.doi.org/10.15226/2374- Page 11 of 12
6890/3/1/00140

Diabetes and Physical Activity

moderate intensity and risk of type 2 diabetes: a systematic review.
Diabetes Care. 2007;30(3):744-52.

194. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM,
Walker EA, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393403.
195. Hu FB, Sigal RJ, Rich-Edwards JW, Colditz GA, Solomon CG, Willett
WC, et al. Walking compared with vigorous physical activity
and risk of type 2 diabetes in women: a prospective study. JAMA.
1999;282(15):1433-9.
196. Hsia J, Wu L, Allen C, Oberman A, Lawson WE, Torrens J, et al.
Physical activity and diabetes risk in postmenopausal women. Am J
Prev Med. 2005;28(1):19-25.

197. Folsom AR, Kushi LH, Hong CP. Physical activity and incident
diabetes mellitus in postmenopausal women. Am J Public Health.
2000;90(1):134-8.
198. Laaksonen DE, Lindstrom J, Lakka TA, Eriksson JG, Niskanen
L, Wikstrom K, et al. Physical activity in the prevention of type
2 diabetes: the Finnish diabetes prevention study. Diabetes.
2005;54(1):158-65.

199. Van Dam RM, Schuit AJ, Feskens EJ, Seidell JC, Kromhout D. Physical
activity and glucose tolerance in elderly men: the Zutphen Elderly
study. Med Sci Sports Exerc. 2002;34(7):1132-6.
200. Albright A, Franz M, Hornsby G, Kriska A, Marrero D, Ullrich I, et al.
American College of Sports Medicine position stand. Exercise and
type 2 diabetes. Med Sci Sports Exerc. 2000;32(7):1345-60.
201. Joslin P. The treatment of diabetes mellitus. Febiger La, editor.
Philadelphia: 1959.
202. Christmas C, Andersen RA. Exercise and older patients: guidelines
for the clinician. J Am Geriatr Soc. 2000;48(3):318-24.
203. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N,
et al. Reduced mitochondrial density and increased IRS-1 serine

Copyright:
© 2016 Banu
phosphorylation in muscle of insulin-resistant offspring of type 2
diabetic parents. J Clin Invest. 2005;115(12):3587-93.

204. Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy
in chronic disease. Scand J Med Sci Sports. 2006;16 Suppl 1:3-63.

205. Ebeling P, Bourey R, Koranyi L, Tuominen JA, Groop LC, Henriksson
J, et al. Mechanism of enhanced insulin sensitivity in athletes.
Increased blood flow, muscle glucose transport protein (GLUT4) concentration, and glycogen synthase activity. J Clin Invest.
1993;92(4):1623-31.
206. Coggan AR, Spina RJ, Kohrt WM, Holloszy JO. Effect of prolonged
exercise on muscle citrate concentration before and after endurance
training in men. Am J Physiol. 1993;264(2 Pt 1):E215-20.
207. Mandroukas K, Krotkiewski M, Hedberg M, Wroblewski Z, Bjorntorp
P, Grimby G. Physical training in obese women. Effects of muscle
morphology, biochemistry and function. Eur J Appl Physiol Occup
Physiol. 1984;52(4):355-61.
208. Saltin B, Henriksson J, Nygaard E, Andersen P, Jansson E. Fiber types
and metabolic potentials of skeletal muscles in sedentary man and
endurance runners Ann N Y Acad Sci. 1977;301:3-29.

209. McAllister RM, Hirai T, Musch TI. Contribution of endotheliumderived nitric oxide (EDNO) to the skeletal muscle blood flow
response to exercise. Med Sci Sports Exerc. 1995;27(8):1145-51.
210. Morris CK, Ueshima K, Kawaguchi T, Hideg A, Froelicher VF. The
prognostic value of exercise capacity: a review of the literature. Am
Heart J. 1991;122(5):1423-31.
211. Phillips EM, Schneider JC, Mercer GR. Motivating elders to initiate
and maintain exercise. Arch Phys Med Rehabil. 2004;85(7 Suppl
3):S52-7.
212. Willey KA, Singh MA. Battling insulin resistance in elderly obese
people with type 2 diabetes: bring on the heavy weights. Diabetes
Care. 2003;26(5):1580-8.

Citation: Banu J (2016) Diabetes and Physical Activity. J Endocrinol Diab 3(1): 1-12. DOI: http://dx.doi.org/10.15226/2374- Page 12 of 12
6890/3/1/00140

